2025-10-30 09:45Revenue and Profit - Revenue for the third quarter reached ¥621,879,591.47, an increase of 33.13% compared to the same period last year[4] - Total profit for the third quarter was -¥101,131,912.31, with a year-to-date total profit of -¥550,700,575.38[4] - Net profit attributable to shareholders for the third quarter was -¥101,131,912.31, and year-to-date net profit was -¥550,700,575.38[4] - Total operating revenue for the first three quarters of 2025 reached ¥1,719,833,029.78, a significant increase of 42.2% compared to ¥1,208,874,280.23 in the same period of 2024[18] - The company reported a net loss of ¥550,700,575.38 for the first three quarters of 2025, an improvement from a net loss of ¥1,071,426,638.90 in the same period of 2024[19] - The basic and diluted earnings per share improved to -¥1.01 from -¥1.99 year-over-year[19] Research and Development - Research and development expenses totaled ¥243,367,673.06 for the third quarter, a decrease of 29.90% year-over-year[5] - R&D expenses accounted for 39.13% of revenue in the third quarter, down 43.63 percentage points from the previous year[5] - Research and development expenses decreased to ¥890,583,907.36, down from ¥1,153,407,440.34 year-over-year[18] Assets and Liabilities - Total assets increased to ¥5,977,129,884.12, reflecting an 8.70% increase from the end of the previous year[5] - The company reported current assets totaling approximately RMB 2.72 billion, an increase from RMB 2.29 billion at the end of the previous period[16] - Total assets reached approximately RMB 5.98 billion, compared to RMB 5.50 billion at the end of the previous period[16] - The total liabilities increased to ¥3,657,046,820.48, up from ¥3,512,317,547.88 year-over-year[17] - The company’s total liabilities include short-term borrowings of approximately RMB 1.07 billion, slightly down from RMB 1.08 billion[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,267, with 15,248 A-share shareholders and 19 H-share shareholders[15] - The company has a total of 208,569,228 shares held by HKSCC NOMINEES LIMITED, representing 37.01% of the total shares[13] - The second largest shareholder, Yantai Rongda Venture Capital Center, holds 102,381,891 shares, accounting for 18.17%[13] Cash Flow and Financing - Net cash flow from operating activities improved to ¥217,057,433.94, compared to a net outflow of ¥835,103,066.88 in the first three quarters of 2024[22] - Cash and cash equivalents amounted to RMB 1.07 billion, up from RMB 762.49 million in the previous period[16] - Cash and cash equivalents at the end of the period increased to ¥1,067,390,134.52, compared to ¥662,006,223.96 at the end of the same period in 2024[22] - The company generated ¥2,117,271,291.07 in cash inflows from financing activities, compared to ¥1,316,625,345.48 in the same period of 2024[22] Strategic Developments - The company expects to benefit from a licensing agreement with Vor Bio, which will provide exclusive rights for the development and commercialization of its proprietary drug outside of Greater China[10] - The increase in revenue is attributed to higher sales of injectable drugs, specifically TaiTasi and VidiXimab[10] - The company reported a significant reduction in clinical trial costs due to the licensing agreement, contributing to a decrease in overall losses[10] Investments and Inventory - The company has invested RMB 535.49 million in construction projects, an increase from RMB 283.23 million previously[16] - The company’s inventory stands at RMB 657.58 million, showing a slight decrease from RMB 659.37 million[16]